JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB120138

Nimodipine, L-type Ca2+ channel blocker

Be the first to review this product! Submit a review

|

(4 Publications)

MW 418.4 Da, Purity >98%. L-type Ca2+ channel blocker. Potent cerebrovasodilator. Cognitive enhancer. More lipophilic than nifedipine (ab120135).
2 Images
Functional Studies - Nimodipine, L-type Ca2+ channel blocker (AB120138)
  • FuncS

Unknown

Functional Studies - Nimodipine, L-type Ca2+ channel blocker (AB120138)

ab2770 staining aryl hydrocarbon receptor in MDA-MB-231 cells treated with nimodipine (ab120138), by ICC/IF. Increase in aryl hydrocarbon receptor expression correlates with increased concentration of nimodipine, as described in literature.
The cells were incubated at 37°C for 6h in media containing different concentrations of ab120138 (nimodipine) in DMSO, fixed with 100% methanol for 5 minutes at -20°C and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab2770 (1/100 dilution) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight® 488 goat anti-mouse polyclonal antibody (ab96879) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.

Chemical Structure - Nimodipine, L-type Ca2+ channel blocker (AB120138)
  • Chemical Structure

Lab

Chemical Structure - Nimodipine, L-type Ca2+ channel blocker (AB120138)

2D chemical structure image of ab120138, Nimodipine, L-type Ca2+ channel blocker

Key facts

CAS number

66085-59-4

Purity

>98%

Form

Solid

form

Molecular weight

418.4 Da

Molecular formula

C<sub>2</sub><sub>1</sub>H<sub>2</sub><sub>6</sub>N<sub>2</sub>O<sub>7</sub>

PubChem

4497

Nature

Synthetic

Solubility

Soluble in DMSO to 100 mM

Soluble in ethanol to 10 mM

Biochemical name

Nimodipine

Biological description

L-type Ca2+ channel blocker. Potent cerebrovasodilator. Cognitive enhancer. More lipophilic than nifedipine (ab120135).

Canonical smiles

CC1=C(C(C(=C(N1)C)C(=O)OC(C)C)C2=CC(=CC=C2)[N+](=O)[O-])C(=O)OCCOC

InChi

InChI=1S/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3

InChiKey

UIAGMCDKSXEBJQ-UHFFFAOYSA-N

IUPAC Name

3-O-(2-methoxyethyl) 5-O-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

Product details

Nimodipine is light sensitive and it is recommended that the compound is protected from light.

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
Ambient
Appropriate long-term storage conditions
Ambient
Storage information
The product can be stored for up to 12 months

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Parkin also known as PARK2 is a protein with a mass of approximately 52 kDa. This protein functions as an E3 ubiquitin ligase and it is an important part of the ubiquitin-proteasome system which tags proteins for degradation. Parkin is expressed across several tissues with significant levels found in the brain particularly in dopaminergic neurons. The progesterone receptor weighing around 98 kDa binds progesterone and activates transcription of target genes. It is expressed in reproductive tissues like the uterus and breast. CACNA1C (Cav1.2) forms an L-type calcium channel subunit and weighs around 260 kDa. It is found in the heart and brain. Cannabinoid Receptor I known as CB1 weighing about 52 kDa is a G-protein coupled receptor highly expressed in the central nervous system.
Biological function summary

These targets show distinct roles in cellular functions. Parkin participates in mitochondrial quality control often forming a complex with PINK1 to mediate mitophagy. The progesterone receptor regulates genes involved in reproductive tissue development and maintenance. CACNA1C plays a pivotal role in calcium entry into cells influencing cardiac muscle contraction. Cannabinoid Receptor I inhibits adenylate cyclase affecting neurotransmitter release. Cytochrome P450 1A2 and 3A4/CYP3A4 perform important functions in drug metabolism. These enzymes contribute to the oxidative metabolism of a variety of substrates. Maxi Potassium channel alpha/SLO and its beta subunits like KCNMB1 affect neuron excitability by conducting potassium ions. TDP1 repairs DNA single-strand breaks. The adenosine A3 receptor influences anti-inflammatory pathways.

Pathways

Parkin and related proteins such as Ubiquitin C are involved in the ubiquitin-dependent catabolic pathway correlating with the autophagy process for cellular quality control. The progesterone receptor takes part in the steroid hormone signaling pathway working alongside estrogen receptors for gene expression control. The calcium signaling pathway includes CACNA1C and closely associates with other calcium channels like RyR2. Cannabinoid Receptor I aligns with the endocannabinoid signaling pathway. Cytochrome P450 isoenzymes CYP1A2 and CYP3A4 interact in the xenobiotic metabolism pathway involving substrates like drugs and carcinogens. Maxi potassium channel proteins regulate neural signaling pathways.

Parkin mutations are implicated in autosomal recessive juvenile Parkinson's disease with PINK1 as a related protein. Mutations in the progesterone receptor can result in reproductive system disorders including certain breast cancers closely linked to estrogen receptor pathways. Variants in CACNA1C associate with disorders like Timothy syndrome which affects the heart and brain. Cannabinoid Receptor I disruption can influence neuropsychiatric conditions such as pharmacologically targeting this receptor impacts alleviation of symptoms in schizophrenia. Cytochrome P450 enzymes like CYP3A4 alterations can contribute to adverse drug reactions. Dysfunctions in the maxi potassium channels relate to epilepsy and other neural disorders with KCNMB1 being another contributing factor.

Product protocols

Publications (4)

Recent publications for all applications. Explore the full list and refine your search

Cell reports 29:317-331.e5 PubMed31597094

2019

The Amyloid Precursor Protein C-Terminal Domain Alters CA1 Neuron Firing, Modifying Hippocampus Oscillations and Impairing Spatial Memory Encoding.

Applications

Unspecified application

Species

Unspecified reactive species

Paula A Pousinha,Xavier Mouska,Daniela Bianchi,Mariana Temido-Ferreira,Joana Rajão-Saraiva,Rui Gomes,Sebastian P Fernandez,Ana Rita Salgueiro-Pereira,Carine Gandin,Elisabeth F Raymond,Jacques Barik,Romain Goutagny,Ingrid Bethus,Luisa V Lopes,Michele Migliore,Hélène Marie

Neuron 100:564-578.e3 PubMed30293822

2018

Ephaptic Coupling Promotes Synchronous Firing of Cerebellar Purkinje Cells.

Applications

Unspecified application

Species

Unspecified reactive species

Kyung-Seok Han,Chong Guo,Christopher H Chen,Laurens Witter,Tomas Osorno,Wade G Regehr

Biochemical and biophysical research communications 460:88-99 PubMed25998737

2015

Evolutionary and functional perspectives on signaling from neuronal surface to nucleus.

Applications

Unspecified application

Species

Unspecified reactive species

Samuel M Cohen,Boxing Li,Richard W Tsien,Huan Ma

Cell 149:1112-24 PubMed22632974

2012

Ca(V)1 and Ca(V)2 channels engage distinct modes of Ca(2+) signaling to control CREB-dependent gene expression.

Applications

Unspecified application

Species

Unspecified reactive species

Damian G Wheeler,Rachel D Groth,Huan Ma,Curtis F Barrett,Scott F Owen,Parsa Safa,Richard W Tsien
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com